Kymera Therapeutics (KYMR) announced the appointment of Brian Adams, JD, as Chief Legal Officer and Corporate Secretary. Adams is a highly accomplished legal executive with nearly two decades of leadership in the life sciences, spanning corporate development, strategic planning, and governance. He will lead Kymera’s legal, governance, and intellectual property functions. Adams will succeed Ellen Chiniara who is retiring from her role to focus on board service, mentoring and other advisory opportunities.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics: Promising Clinical Developments and Strategic Positioning in STAT6 Landscape Justify Buy Rating
- Kymera Therapeutics’ Earnings Call: Optimism and Strategic Progress
- Kymera Therapeutics: Promising Developments in STAT6 Degrader KT-621 Drive Buy Rating
- Positive Outlook for Kymera Therapeutics Amid Promising KT-621 Developments and Strong Financial Position
- Kymera Therapeutics: Strategic Advancements and Financial Strength Drive Buy Rating